Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Impact of early tumor shrinkage on quality of life in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: results of Phase II QUACK trial

Fig. 3

Association of ETS with HRQOL from baseline throughout the study period of 24 weeks using a linear mixed-effects model for repeated measures. The least squares means of the score at each time point were determined for the GHS/QOL and five functional (physical, role, emotional, cognitive, social) scales

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us